News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Abbott Laboratories Tricor Fails Main Goal In Diabetes Trial
November 14, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Abbott Laboratories Inc.'s drug to lower blood fats called triglycerides failed its primary goal in a large trial of significantly reducing heart attacks and coronary deaths among patients with type II diabetes, researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Abbott Laboratories
MORE ON THIS TOPIC
Diabetes
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
September 22, 2026
·
2 min read
·
Annalee Armstrong
Sponsored by AGC Biologics
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
September 21, 2026
·
7 min read
·
AGC Biologics
IPO
Electra lights up with $350M IPO for pivotal immune-disease drug development
September 18, 2026
·
1 min read
·
Gabrielle Masson
Neuropsychiatric disorders
Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
September 18, 2026
·
4 min read
·
Annalee Armstrong
